Centauri Therapeutics Limited (GB/GB)
USPTO PatentsView assignee record - 6 granted patents across 6 technology areas, recorded in grant years 2021–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Centauri ranks #39,382 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 6 technology areas.
- #39,382
- of 49,997 US assignees by volume
- 47th percentile
- by Innovation Score (34.3/100)
- 20.3
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R39382 · Foreign Corporation #39,382 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 6 grants
- LOWER-Q #39,382/49,997
- PHOTO-FINISH Cell Command
- CPC-NARROW A61P · 6 areas
- INNOV-THIN 34.3/100
- CLAIMS-DENSE 20.3 claims/avg
- TYPE-FRNCORP Foreign Corp
- SPAN-YRS 2021–2024 · 4y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Cell Command Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Centauri’s 34.3 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Centauri
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Centauri Therapeutic… · this assignee
Centauri Therapeutic… · this assignee
34 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Centauri's Innovation Score is 34.3/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Centauri?
Each dot is one of Centauri’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Centauri’s own 20.3 claims/patent is ABOVE the 13.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Centauri's grants concentrate
Centauri Therapeutics Limited (GB/GB) is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2022. By volume, Centauri sits between Cell Command Inc. and Cerasina GmbH.
Centauri's three-year grant acceleration
Centauri Therapeutics Limited (GB/GB) shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Centauri's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Cell Command
Cell Command Inc.
6 patents
- Cellmo Materials…
CellMo Materials and Innovation, Inc.
6 patents
- Cellmobility
CellMobility, Inc.
6 patents
- Cellmosaic
CellMosaic Inc.
6 patents
- Center for Deep L…
Center for Deep Learning in Electronics Manufacturing
6 patents
- Center for Excell…
Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences
6 patents
- Centrotherm Photo…
Centrotherm Photovoltaics AG
6 patents
- Cerasina
Cerasina GmbH
6 patents
- Centauri Therapeu… ◀
Centauri Therapeutics Limited (GB/GB)
6 patents
What this shows Centauri holds 6 patents at rank #39,528, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Centauri
By rank, the assignees closest to #39,528 in granted patent volume.
- Cell Command Inc. #39,524 · 6 patents
- CellMo Materials and Innovation, Inc. #39,525 · 6 patents
- CellMobility, Inc. #39,526 · 6 patents
- CellMosaic Inc. #39,527 · 6 patents
- Center for Deep Learning in Electronics Manufacturing #39,529 · 6 patents
- Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences #39,530 · 6 patents
- Centrotherm Photovoltaics AG #39,531 · 6 patents
- Cerasina GmbH #39,532 · 6 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Centauri's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Centauri's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 47th percentile higher than 47% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 3 | 50.0% |
| 2022 | 1 | 16.7% |
| 2023 | 1 | 16.7% |
| 2024 | 1 | 16.7% |
Which technologies does Centauri Therapeutics Limited (GB/GB) patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Centauri Therapeutics Limited (GB/GB)'s patent record in context - here's where to go next.
- Centauri Therapeutics Limited (GB/GB)'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #39,382 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Centauri Therapeutics Limited (GB/GB) against Cell Command Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 34.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.